Preferred Label : KRAS G12C Inhibitor BEBT-607;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C,
with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor
BEBT-607 selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated
signaling. This may halt proliferation and metastasis in KRAS G12C mutated tumor cells.
KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling,
division and differentiation. Mutations of KRAS may induce constitutive signal transduction
leading to tumor cell proliferation, invasion, and metastasis.;
Molecule name : BEBT 607; BEBT-607;
Origin ID : C203654;
concept_is_in_subset
- has_target
